Urology · Mobile, AL
NPI
1073804209
Since 2011
Specialty
Urology
Code 208800000X
Group practices
1
Medicare group memberships
Hospitals
4
Hospital affiliations
168 Mobile Infirmary Blvd
Mobile, AL, 36607
Phone (251) 433-1895
Groups this clinician bills Medicare through
Medicare paid, 2024
$644K
22,188 services
Medicare patients, 2024
1,085
Average age 74
Drug cost, 2024
$15.8M
3,753 prescriptions
Company payments, 2025
$1,084
From 14 companies
Procedures and visits billed to Original Medicare, 2024
In 2024, the most common Medicare service billed by Zachary D Reardon was code J0897 (injection, denosumab, 1 mg), 13,080 times for 37 patients. In total Zachary D Reardon billed 22,188 services in 93 codes, and Medicare paid $644K.
| Code |
|---|
Official US government data: the national provider registry and Medicare enrollment records, linked by NPI. Last update of this record: 2017-02-22.
| Setting |
|---|
| Services |
|---|
| Patients |
|---|
| Paid per service |
|---|
| Medicare paid |
|---|
| J0897 Injection, denosumab, 1 mg | Office | 13,080 | 37 | $19.90 | $260K |
| 84153 Clinical Chemistry | Office | 986 | 664 | $17.88 | $18K |
| 99215 Office E&M - Established | Office | 768 | 404 | $113.42 | $87K |
| G2211 Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's | Office | 694 | 402 | $11.33 | $7,865 |
| 36415 Venipuncture Blood Collection | Office | 475 | 210 | $8.52 | $4,048 |
| J9217 Leuprolide acetate (for depot suspension), 7.5 mg | Office | 435 | 48 | $139.68 | $61K |
| 81000 Clinical Chemistry | Office | 385 | 268 | $3.84 | $1,477 |
| 99490 Chronic, Principal, and Transitional Care Management | Office | 366 | 57 | $44.78 | $16K |
| 84403 Clinical Chemistry | Office | 363 | 179 | $25.12 | $9,118 |
| 99487 Chronic, Principal, and Transitional Care Management | Office | 317 | 36 | $94.11 | $30K |
| 99214 Office E&M - Established | Office | 145 | 128 | $80.51 | $12K |
| 96402 Chemotherapy Administration | Office | 141 | 49 | $22.28 | $3,142 |
| 81002 Clinical Chemistry | Office | 132 | 118 | $3.36 | $444 |
| 96401 Chemotherapy Administration | Office | 126 | 35 | $46.37 | $5,843 |
| 99223 Hospital E&M - Initial | Facility | 92 | 86 | $124.85 | $11K |
By year: 2022 $686K for 23,198 services; 2023 $697K for 18,163 services; 2024 $644K for 22,188 services.
Lab tests billed to Medicare, 2024
| Test code | Tests | Patients | Paid per test | Medicare paid |
|---|---|---|---|---|
| 84153 Clinical Chemistry | 986 | 664 | $17.88 | $18K |
| 36415 Venipuncture Blood Collection | 475 | 210 | $8.52 | $4,048 |
| 81000 Clinical Chemistry | 385 | 268 | $3.84 | $1,477 |
| 84403 Clinical Chemistry | 363 | 179 | $25.12 | $9,118 |
| 81002 Clinical Chemistry | 132 | 118 | $3.36 | $444 |
| 84154 Clinical Chemistry | 76 | 59 | $18.02 | $1,370 |
| 82670 Clinical Chemistry | 61 | 49 | $27.00 | $1,647 |
| 82565 Clinical Chemistry | 28 | 28 | $5.02 | $141 |
| 85014 Blood Count | 18 | 13 | $2.19 | $39.44 |
| 85018 Blood Count | 17 | 12 | $2.18 | $37.12 |
Medicare prescription drug claims, 2024
In 2024, the drug Zachary D Reardon prescribed most often to Medicare patients was Tamsulosin Hcl, with 679 prescriptions and refills. In total Zachary D Reardon wrote 3,753 Medicare prescriptions that cost $15.8M.
| Drug | Claims | 30-day fills | Patients | Cost |
|---|---|---|---|---|
| Tamsulosin Hcl Generic | 679 | 1,708 | 246 | $11K |
| Xtandi Enzalutamide | 506 | 506 | 63 | $6.7M |
| Orgovyx Relugolix | 470 | 470 | 63 | $1.2M |
| Erleada Apalutamide | 370 | 370 | 42 | $5.3M |
| Finasteride Generic | 172 | 474 | 53 | $2,030 |
| Nubeqa Darolutamide | 159 | 159 | 21 | $2.1M |
| Prednisone Generic | 129 | 129 | 27 | $703 |
| Abiraterone Acetate Generic | 124 | 124 | 22 | $197K |
| Cefdinir Generic | 110 | 110 | 89 | $1,792 |
| Ciprofloxacin Hcl Generic | 108 | 108 | 96 | $769 |
| Oxycodone-Acetaminophen Oxycodone Hcl/Acetaminophen | 102 | 102 | 84 | $621 |
| Myrbetriq Mirabegron | 92 | 128 | 25 | $57K |
| Methenamine Hippurate Generic | 74 | 122 | 19 | $5,714 |
| Oxybutynin Chloride Er Oxybutynin Chloride | 67 | 183 | 26 | $1,636 |
| Estradiol Generic | 66 | 123 | 28 | $4,589 |
Brand drugs: - claims; generic drugs: 2,074 claims; opioid claims: 133.
Money and other things of value reported by the companies
In 2025, drug and medical device companies paid Zachary D Reardon $1,084 ($1,084 in general payments such as food, travel and fees) from 14 companies. The largest payer was Janssen Biotech, Inc. with $206.
| Company | Payments | Amount |
|---|---|---|
| Janssen Biotech, Inc. JNJ | 9 | $206 |
| Pfizer Inc. PFE | 14 | $172 |
| Dendreon Pharmaceuticals LLC | 4 | $121 |
| Novartis Pharmaceuticals Corporation NVS | 7 | $112 |
| Bayer Healthcare Pharmaceuticals Inc. BAYN.DE | 5 | $96.83 |
| Urogen Pharma, Inc. URGN | 4 | $81.69 |
| Sumitomo Pharma America, Inc. 4506.T | 4 | $72.15 |
| Myriad Genetic Laboratories, Inc. MYGN | 3 | $64.08 |
| AstraZeneca Pharmaceuticals LP AZN | 2 | $55.3 |
| C. R. Bard, Inc. & Subsidiaries BDX | 1 | $39.4 |
Official US government data on Original Medicare services, Medicare prescription drug plans and the payments drug and device companies must report. Services with fewer than 11 patients and drugs with fewer than 11 claims are not published. Procedure codes are shown by number with their public category.